Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK Rejects Unilever's Bid for Consumer Healthcare Business - Happi
Company News, Financial News

GSK Rejects Unilever’s Bid for Consumer Healthcare Business

The $68 billion offer included an array of oral care brands including Sensodyne and Aquafresh.

GlaxoSmithKline has rejected Unilever's BPS50 billion ($68 billion at current exchange rates) bid for its consumer healthcare business. GSK is ranked No. 12 in Happi's International Top 30. Unilever is ranked No. 1 on the Happi list. Today, Unilever is said to be increasing its offer.

GSK is among the global leaders in the oral care sector with brands like Sensodyne, Dr. Best and Aquafresh. 

In a statement, GSK said that a series of three bids made by Unilever last year, the last on December 20, were all rejected “on the basis that they fundamentally undervalued” the unit and its future prospects. The consumer healthcare business is a joint venture between GSK and Pfizer.

GSK now expects to spin-off the business later this year. After integrating the consumer health businesses of Novartis (2015) and Pfizer (2019), GSK said the business unit attained annual sales of 9.6 billion pounds ($13.1 billion) in 2021.



Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters